CAJ | 학술논문

目的研究间变性大细胞淋巴瘤(ALCL)患者中间变性淋巴瘤激酶(ALK)及磷酸化AKT(p-AKT)、mTOR(p-mTOR)、4E-BPI(p-4E-BPI)和p70S6K(p-p70S6K)的表达特点、临床意义及相互关系.方法应用免疫组织化学EnVision法检测ALK蛋白及p-AKT、p-mTOR、p-4E-BP1、p-p70S6K蛋白的表达.结果 81例ALCL患者中有51例(63.0%)表达ALK蛋白,30例(37.0%)不表达,ALK阳性患者预后优于阴性患者(P<0.05).71例患者中54例(76.1%)表达p-AKT,p-AKT的表达与ALK表达相关(P<0.05);57例(80.3%)表达p-mTOR,p-mTOR的表达与ALK、p-AKT表达相关(P<0.05);64例(90.1%)表达p-4E-BP1,66例(93.0%)表达p-p70S6K,p-4E-BP1及p-p70S6K的表达与p-mTOR表达相关(P<0.05),与ALK、磷酸化p-AKT表达无关(P>0.05).p-AKT、P-mTOR、p-4E-BP1及p-p70S6K的表达与预后无关(P>0.05).COX比例风险回归分析表明ALK的表达、体质性症状对患者生存影响有统计学意义(P<0.05),其中,ALK的表达对生存的影响最大.结论 p-AKT、P-mTOR、p-4E-BP1和p-p70S6K在ALCL患者中均有表达,但在ALK阳性患者中表达率显著高于阴性患者.p-AKT、P-mTOR表达与ALK表达相关,提示在ALK阳性ALCL患者中存在AKT/mTOR通路的激活,但无明显的预后意义.无关(P>0.05).p-AKT、P-mTOR、p-4E-BP1及p-p70S6K的表达与预后无关(P>0.05).COX比例风险回归分表明ALK的表达、体质性症状对患者生存影响有统计学意义(P<0.05),其中,ALK的表达对生存的影响最大.结论 p-AKT、P-mTOR、p-4E-BP1和p-p70S6K在ALCL患者中均有表达,但在ALK阳性患者中表达率显著高于阴性患者.p-AKT、P-mTOR表达与ALK表达相关,提示在ALK阳性ALCL患者中存在AKT/mTOR通路的激活,但无明显的预后意义.无关(P>0.05).
목적 연구간변성대세포림파류(ALCL)환자중간변성림파류격매(ALK)급린산화AKT(p-AKT)、mTOR(p-mTOR)、4E-BPI(p-4E-BPI)화p70S6K(p-p70S6K)적표체특점、림상의의급상호관계.방법 응용면역조직화학EnVision법검측ALK단백급p-AKT、p-mTOR、p-4E-BP1、p-p70S6K단백적표체.결과 81례ALCL환자중유51례(63.0%)표체ALK단백,30례(37.0%)불표체,ALK양성환자예후우우음성환자(P<0.05).71례환자중54례(76.1%)표체p-AKT,p-AKT적표체여ALK표체상관(P<0.05);57례(80.3%)표체p-mTOR,p-mTOR적표체여ALK、p-AKT표체상관(P<0.05);64례(90.1%)표체p-4E-BP1,66례(93.0%)표체p-p70S6K,p-4E-BP1급p-p70S6K적표체여p-mTOR표체상관(P<0.05),여ALK、린산화p-AKT표체무관(P>0.05).p-AKT、P-mTOR、p-4E-BP1급p-p70S6K적표체여예후무관(P>0.05).COX비례풍험회귀분석표명ALK적표체、체질성증상대환자생존영향유통계학의의(P<0.05),기중,ALK적표체대생존적영향최대.결론 p-AKT、P-mTOR、p-4E-BP1화p-p70S6K재ALCL환자중균유표체,단재ALK양성환자중표체솔현저고우음성환자.p-AKT、P-mTOR표체여ALK표체상관,제시재ALK양성ALCL환자중존재AKT/mTOR통로적격활,단무명현적예후의의.무관(P>0.05).p-AKT、P-mTOR、p-4E-BP1급p-p70S6K적표체여예후무관(P>0.05).COX비례풍험회귀분표명ALK적표체、체질성증상대환자생존영향유통계학의의(P<0.05),기중,ALK적표체대생존적영향최대.결론 p-AKT、P-mTOR、p-4E-BP1화p-p70S6K재ALCL환자중균유표체,단재ALK양성환자중표체솔현저고우음성환자.p-AKT、P-mTOR표체여ALK표체상관,제시재ALK양성ALCL환자중존재AKT/mTOR통로적격활,단무명현적예후의의.무관(P>0.05).
Objective To study the expression of anaplastic lymphoma kinase (ALK) and the phosphorylation status of AKT, mammalian target of rapamycin (mTOR), 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase (p70S6K) and their interrelationships and clinical pathological significance in anaplastic large cell lymphoma (ALCL) patients. Methods Immunohistochemical and EnVision methods were used to detect the expression of ALK, p-AKT, p-mTOR, p-4E-BP1 and p-p70S6K. Results Among the 81 ALCL patients,51 (63.0%) expressed ALK, whereas the other 30 (37.0%) did not. Patients with ALK* ALCL had a better prognosis than those with ALK- ALCL (P < 0.05). Out of the 71 ALCL samples studied, p-AKT was detected in 54 (76.1%) samples and its phosphorylation was correlated with ALK expression (P < 0.05) ; p-mTOR was detected in 57 (80.3%) samples and its expression was correlated with beth ALK and p-AKT (P < 0.05) ; p-4E-BP1 and p-p70S6K were detected in 64 (90.1%) and 66 (93.0%) samples respectively, and their expressions were related with p-mTOR (P < 0.05), but not with ALK or p-AKT (P > 0.05). COX Proportional Hazard Model analysis showed that both the expression of ALK and the B symptoms affected the prognosis (P < 0.05), moreover, the former had greater impact than the later. Conclusion Expressions of p-AKT, p-mTOR, p-4E-BP1 and p-p70S6K are detected in ALCL, while ALK+ cases have higher incidence than those with ALK- cases. Phosphorylation of AKT and mTOR is correlated with ALK expression, suggesting that there is an activated pathway of AKT/mTOR in patients with ALK+ ALCL, but the activation have no obvious prognostic significance.